採血筆市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球採血針市場預計將從 2025 年的 26.8 億美元大幅成長至 2031 年的 47.3 億美元，複合年成長率為 9.95%。

採血針是一種無菌、一次性醫療器械，其尖端鋒利，用於毛細血管採血，是血糖監測和各種診斷任務的必備工具。推動其市場成長的主要因素是需要定期驗血的慢性病盛行率不斷上升，以及患者自我監測需求的日益成長。全球人口老化和嚴格的感染控制通訊協定（要求使用一次性安全器械）進一步加劇了這一成長趨勢。根據國際糖尿病聯盟的數據，到2024年，全球將有約5.89億成年人患有糖尿病，將對常規監測用品產生持續且龐大的需求。

儘管成長前景強勁，但挑戰依然存在，主要源自於頻繁的皮膚穿刺帶來的疼痛和不適。這些都會對患者的依從性產生負面影響，並削弱疾病管理的有效性。此外，糖尿病管理產品報銷政策不完善，限制了發展中地區患者獲得這些重要工具的機會，從而阻礙了市場進一步擴張。

市場促進因素

全球採血針市場的主要驅動力是糖尿病和其他慢性疾病在全球範圍內的日益普及。有效控制血糖需要頻繁進行毛細血管採血。這一普遍存在的健康挑戰導致對無菌採血針針的需求持續成長，尤其是在家庭自我管理療法中，這對於預防長期併發症至關重要。美國疾病管制與預防中心 (CDC) 於 2024 年 5 月發布的《國家糖尿病統計報告》凸顯了這項需求的規模。報告指出，美國有 3,840 萬名糖尿病患者，這意味著龐大的人口依賴日常診斷耗材。因此，醫療保健系統正在大力投資管理用品，國際糖尿病聯盟 (IDF) 估計，到 2024 年，全球與糖尿病相關的醫療保健支出將達到 1 兆美元，這凸顯了採血針等護理產品的巨大經濟影響。

同時，由於旨在預防事故的安全採血針的廣泛應用，市場格局正在重塑。這一趨勢的驅動力在於嚴格的監管要求以及臨床環境中對職業安全日益成長的關注。醫療機構正在逐步淘汰標準設備，轉而使用帶有存儲機制的安全採血針，以最大限度地降低意外刺傷和病原體傳播的風險。鑑於感染疾病的普遍存在，這種轉變至關重要，因為在診斷過程中必須確保操作安全。正如世界衛生組織（世衛組織）於2024年4月發布的《2024年全球肝炎報告》所指出的，全球約有2.54億人患有慢性乙型肝炎，凸顯了使用安全設計工具以確保醫護人員在血液篩檢測試中安全的重要性。

市場挑戰

全球採血針市場成長的主要障礙在於發展中地區缺乏完善的報銷政策和有限的取得途徑。儘管定期血糖監測的臨床需求毋庸置疑，但在公共醫療保險不足的低收入地區，這些必需耗材的費用往往由患者自行承擔。這種經濟壓力迫使許多用戶節約使用耗材，導致一次性採血採血針的重複使用（存在安全隱患）以及檢測頻率降低。這些行為直接減少了銷售量對於市場收入至關重要。

糖尿病治療成本的飆升反映了這項經濟挑戰的嚴峻性，給醫療保健預算帶來了沉重負擔，並限制了一次性診斷設備的資金投入。根據國際糖尿病聯盟（IDF）估計，到2024年，全球糖尿病醫療支出預計將達到1.015兆美元。如此巨大的財政負擔迫使支付方和政府機構優先考慮急性治療，並在資源匱乏的環境中推遲對監測設備的投資，從而阻礙了高成長地區的市場滲透。因此，資金籌措機制的差異已成為一個主要瓶頸，阻礙了市場充分利用新興經濟體日益成長的糖尿病盛行率。

市場趨勢

全球採血針市場正經歷著微針採血技術的顯著成長，該技術消除了傳統指尖採血帶來的不適感。這些先進的設備採用細針排列，可無痛採集毛細血管血，直接降低患者的焦慮，並有助於提高患者對常規檢查的依從性。這項技術進步在分散式臨床試驗和居家診斷中尤其重要，因為使用者體驗對於準確收集數據至關重要。在2025年3月發布的商業性進展新聞稿中，Tasso確認其以患者為中心的採血設備銷量已超過150萬台，證實了市場對近乎無痛採樣解決方案日益成長的需求。

同時，為了減少一次性診斷耗材對環境的影響，醫療產業正穩步轉向使用永續和環保材料。製造商積極審查其生產流程，以減少塑膠廢棄物，並將回收聚合物應用於設備機殼，同時保持嚴格的無菌性和性能標準。這項策略轉變直接回應了監管機構和相關部門日益成長的需求，即減少日常一次性產品產生的巨量醫療廢棄物。例如，Greiner AG於2025年5月發布的《2024年度永續發展報告》強調，該公司在2024年將其集團整體廢棄物總量減少了17%，這表明整個產業正在努力將循環經濟原則應用於製造供應鏈。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球採血設備市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（安全採血針、標準採血針、特殊採血針）
  • 依應用領域（血糖測量、血紅素測量、血液凝固檢驗及其他應用）
  • 按最終使用者（醫院/診所、居家醫療環境、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美採血設備市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲採血設備市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區採血設備市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲採血設備市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲採血設備市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球採血設備市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• B. Braun SE
• Terumo Medical Corporation
• Owen Mumford Ltd
• HTL-STREFA SA（MTD Medical Technology and Devices SpA）
• ARKRAY, Inc
• Sarstedt AG & Co. KG
• Medline Industries, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Lancets Market is projected to expand significantly, rising from a valuation of USD 2.68 Billion in 2025 to USD 4.73 Billion by 2031, reflecting a CAGR of 9.95%. As sterile, single-use medical instruments equipped with sharp points for capillary blood sampling, lancets are indispensable for glucose monitoring and various diagnostic tasks. Growth is primarily propelled by the increasing incidence of chronic diseases that necessitate regular blood testing and the growing need for patients to perform self-monitoring. This upward trend is reinforced by an aging global demographic and stringent infection control protocols that dictate the use of disposable safety mechanisms. Data from the International Diabetes Federation indicates that approximately 589 million adults were living with diabetes globally in 2024, generating a consistent and substantial demand for daily monitoring supplies.

Despite this robust growth outlook, the market encounters obstacles stemming from the pain and discomfort caused by frequent skin punctures, which can negatively impact patient compliance and compromise disease management efficacy. Furthermore, the accessibility of these essential tools is restricted in developing regions due to insufficient reimbursement policies for diabetes management supplies, which ultimately limits the market's broader expansion.

Market Driver

The primary force driving the Global Lancets Market is the rising global prevalence of diabetes and other chronic conditions, which necessitates frequent capillary blood sampling to maintain effective glycemic control. This widespread health challenge creates an enduring demand for sterile lancing devices, especially for home-based self-monitoring regimens that are vital for averting long-term complications. The scale of this requirement is highlighted by the Centers for Disease Control and Prevention's 'National Diabetes Statistics Report' from May 2024, which identified 38.4 million individuals with diabetes in the United States, indicating a massive population dependent on daily diagnostic consumables. Consequently, healthcare systems are investing heavily in management supplies, with the International Diabetes Federation estimating global health expenditure on diabetes reached USD 1 trillion in 2024, underscoring the significant economic impact of care products like lancets.

Simultaneously, the market is being reshaped by the increasing adoption of safety lancets designed to prevent needlestick injuries, a trend driven by strict regulatory requirements and a heightened focus on occupational safety within clinical settings. Medical facilities are progressively replacing standard devices with engineered safety lancets featuring retractable mechanisms to minimize the risk of accidental punctures and pathogen transmission. This shift is essential given the prevalence of infectious diseases that demand secure handling during diagnostics. As noted in the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, roughly 254 million people globally were living with chronic hepatitis B, emphasizing the critical need for safety-engineered tools to safeguard healthcare workers during blood screening procedures.

Market Challenge

A significant hurdle impeding the growth of the global lancets market is the lack of adequate reimbursement policies and limited accessibility within developing regions. Although the clinical requirement for regular blood glucose monitoring is undeniable, the financial responsibility for these necessary supplies frequently falls on patients in lower-income groups where public health coverage is lacking. This economic pressure compels many users to ration their supplies, leading to the hazardous reuse of single-use lancets or a decrease in testing frequency, behaviors that directly reduce the volume of consumable sales essential for market revenue.

The severity of this economic challenge is reflected in the escalating costs of diabetes care, which exert tremendous strain on healthcare budgets and restrict funding for disposable diagnostics. The International Diabetes Federation reported that diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This massive financial burden forces payers and government entities in resource-limited settings to prioritize acute medications over monitoring devices, effectively hindering market penetration in regions with high growth potential. As a result, disparities in funding mechanisms create a major bottleneck, preventing the market from fully leveraging the increasing disease prevalence in emerging economies.

Market Trends

The Global Lancets Market is witnessing a distinct rise in microneedle-based blood collection technologies aimed at eliminating the discomfort linked to conventional fingersticks. These advanced devices employ microscopic arrays to obtain capillary blood without pain, directly mitigating patient anxiety and enhancing adherence to regular testing schedules. This technological evolution is particularly significant for decentralized clinical trials and home-based diagnostics, where user experience is critical for accurate data collection. In a press statement from March 2025 regarding its commercial advancements, Tasso, Inc. confirmed the sale of over 1.5 million of its patient-centric blood collection devices, confirming the growing market appetite for virtually pain-free sampling solutions.

In parallel, the industry is shifting robustly toward the use of sustainable and eco-friendly materials to reduce the environmental impact of single-use diagnostic consumables. Manufacturers are actively reworking production methods to decrease plastic waste and are integrating recycled polymers into device casings while maintaining strict sterility and performance standards. This strategic move is a direct response to increasing regulatory and institutional demands to cut down the substantial volume of medical waste resulting from daily disposable items. For instance, Greiner AG's 'Annual and Sustainability Report 2024', released in May 2025, highlighted that the company achieved a 17% reduction in its group-wide total waste volume in 2024, demonstrating a sector-wide dedication to applying circular economy principles within the manufacturing supply chain.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Ypsomed AG
• B. Braun SE
• Terumo Medical Corporation
• Owen Mumford Ltd
• HTL-STREFA S.A. (MTD Medical Technology and Devices S.p.A.)
• ARKRAY, Inc
• Sarstedt AG & Co. KG
• Medline Industries, Inc.

Report Scope

In this report, the Global Lancets Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lancets Market, By Type

• Safety Lancets
• Standard Lancets
• Specialty Lancets

Lancets Market, By Application

• Glucose Testing
• Haemoglobin Testing
• Coagulation Testing
• Other Applications

Lancets Market, By End User

• Hospitals and Clinics
• Home Care Settings
• Others

Lancets Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lancets Market.

Available Customizations:

Global Lancets Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lancets Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Safety Lancets, Standard Lancets, Specialty Lancets)
  • 5.2.2. By Application (Glucose Testing, Haemoglobin Testing, Coagulation Testing, Other Applications)
  • 5.2.3. By End User (Hospitals and Clinics, Home Care Settings, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lancets Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lancets Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Lancets Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Lancets Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Lancets Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lancets Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Lancets Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Lancets Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Lancets Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Lancets Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Lancets Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lancets Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Lancets Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Lancets Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Lancets Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Lancets Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Lancets Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lancets Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Lancets Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Lancets Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Lancets Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lancets Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Lancets Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Lancets Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lancets Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Ypsomed AG
• 15.3. B. Braun SE
• 15.4. Terumo Medical Corporation
• 15.5. Owen Mumford Ltd
• 15.6. HTL-STREFA S.A. (MTD Medical Technology and Devices S.p.A.)
• 15.7. ARKRAY, Inc
• 15.8. Sarstedt AG & Co. KG
• 15.9. Medline Industries, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer